Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Panacea Life Sciences Holdings, Inc. (PLSH)
USD0.10
+0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address
5910 South University Boulevard 80121
Greenwood Village, CO, US
Greenwood Village, CO, US
CEO
Leslie A. Buttorff
Website
panacealife.com
IPO
2022-04-04
CIK 1552189 ISIN US69810P1093
Description
Panacea Life Sciences Holdings, Inc. operates as an integrated research and production firm, specializing in cannabinoid and nutraceutical products across the entire supply chain, from sourcing to final sale. Its core mission is to develop and deliver natural, pharmaceutical-grade alternatives for both human and pet consumption. The company's diverse product range encompasses items such as softgels, edible gummies, liquid tinctures, sublingual tablets, and a variety of cosmetic and topical applications. In addition to these offerings, the company is involved in the personal protective equipment (PPE) market, importing and distributing hand sanitizers and masks. Panacea Life Sciences also provides white-label and contract manufacturing services to other cannabinoid companies, sells raw materials, and manages tolling arrangements. Established in 2008, the company is headquartered in Greenwood Village, Colorado.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.10
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
23.8K
Beta
2.68
Float Shares
10.13M
Free Float %
47.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +5.49% | +1.69% | -25.56% | -33.26% | -50.00% | -40.00% | -40.00% | -93.48% | -95.71% | -95.71% | -95.71% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.10
DCF (Unlevered)
0.03
-74.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-25.46
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-77.8% Q1'26: -80.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+77.9% ★ Q1'26: -29,850.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-612.9% Q1'26: -85.5% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%-192.6% Q1'26: -126.1% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-31.6% Q1'26: -11.0% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+222.7% Q1'26: +195.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×11.81× Q1'26: -1.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
345.7K
est: 1.90M (-81.8%)
|
9.02M
est: 7.60M (+18.7%)
|
910.5K
est: 910.5K (+0.0%)
|
956.0K
956.0K – 956.0K
+5.0% YoY
|
1.90M
1.90M – 1.90M
+98.7% YoY
|
7.60M
7.60M – 7.60M
+300.0% YoY
|
| EBITDA |
-8.65M
est: -981.9K (-780.7%)
|
-2.03M
est: -3.93M (+48.4%)
|
18.2K
est: -425.9K (+104.3%)
|
-447.2K
-447.2K – -447.2K
-5.0% YoY
|
-888.8K
-888.8K – -888.8K
-98.7% YoY
|
-3.56M
-3.56M – -3.56M
-300.0% YoY
|
| EBIT |
-9.54M
est: -1.18M (-707.2%)
|
-3.72M
est: -4.73M (+21.3%)
|
-1.75M
est: -673.4K (-160.4%)
|
-707.0K
-707.0K – -707.0K
-5.0% YoY
|
-1.41M
-1.41M – -1.41M
-98.7% YoY
|
-5.62M
-5.62M – -5.62M
-300.0% YoY
|
| Net Income |
-9.48M
est: -371.50M (+97.4%)
|
-6.99M
est: -165.11M (+95.8%)
|
-416.7K
est: -1.47B (+100.0%)
|
-1.33B
-1.33B – -1.33B
+9.1% YoY
|
-1.20B
-1.20B – -1.20B
+10.0% YoY
|
-532.89M
-532.89M – -532.89M
+55.6% YoY
|
| SGA |
8.95M
est: 1.39M (+545.0%)
|
2.81M
est: 5.55M (-49.4%)
|
533.8K
est: 715.1K (-25.4%)
|
750.8K
750.8K – 750.8K
+5.0% YoY
|
1.49M
1.49M – 1.49M
+98.7% YoY
|
5.97M
5.97M – 5.97M
+300.0% YoY
|
| EPS |
-7.83
est: -20.16 (+61.2%)
|
-0.41
est: -8.96 (+95.4%)
|
-0.01
est: -24.64 (+100.0%)
|
-22.40
-22.40 – -22.40
+9.1% YoY
|
-20.16
-20.16 – -20.16
+10.0% YoY
|
-8.96
-8.96 – -8.96
+55.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-9.04M
OE per share TTM
-0.23
Owner's Yield
-534.39%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
281.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
10
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 22nd Century Group, Inc. | 91.02M | 15.20% | — | 91.02M | — | — | CO | Nevada | 2021-07-09 | ↗ |
| 2 | Ceed2Med, LLC | 67.09M | 57.36% | 67.09M | — | 67.09M | 10.00 | CO | 6. Citizenship or Place of Organization | 2019-01-22 | ↗ |
| 3 | Paradox Capital Partners, LLC | 13.73M | 9.99% | 13.00M | 726.9K | 13.00M | 726.9K | PN | — | 2021-02-08 | ↗ |
| 4 | Vladislav (Bobby) Yampolsky | 7.64M | 22.20% | 7.64M | — | 7.64M | 10.00 | OO | or Place of Organization | 2019-07-29 | ↗ |
| 5 | Real Estate Company, LLC | 7.30M | 47.00% | 7.30M | — | 7.30M | — | CO | Colorado | 2023-06-23 | ↗ |
| 6 | Buttorff | 1.54M | 9.90% | 1.54M | — | 1.54M | — | IN | Colorado | 2023-06-23 | ↗ |
| 7 | Harvey Kesner | 326.8K | 0.40% | 326.8K | — | 326.8K | 11.00 | IN | — | 2021-02-08 | ↗ |
| 8 | Harvey & Renee Kesner JTWROS | 250.0K | 0.31% | 250.0K | — | 250.0K | 11.00 | IN | — | 2021-02-08 | ↗ |
| 9 | Darwin Capital Investments, LLC | 150.0K | 0.18% | 150.0K | — | 150.0K | 11.00 | PN | — | 2021-02-08 | ↗ |
| 10 | Renee Kesner | 134.00 | 0.00% | 134.00 | — | 134.00 | 11.00 | IN | — | 2021-02-08 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
1
Sells
0
Shares acquired
20.0K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+20,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-18 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 20,000 | 0.24 | 4.7K | 1,533,949 | — | ↗ |
| 2023-06-09 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,000 | 0.43 | 1.3K | 1,513,949 | — | ↗ |
| 2023-06-02 | Buttorff Leslie | Director / Officer / 10% Owner | A-Award | A | Common Stock | 760,000 | 0.50 | 380.0K | 1,510,949 | — | ↗ |
| 2023-05-23 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 500 | 0.50 | 249.00 | 751,449 | — | ↗ |
| 2023-05-19 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,500 | 0.52 | 780.00 | 750,949 | — | ↗ |
| 2023-05-09 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,300 | 0.38 | 867.10 | 741,949 | — | ↗ |
| 2023-05-08 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,500 | 0.43 | 645.00 | 739,649 | — | ↗ |
| 2023-05-05 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 11,500 | 0.49 | 5.6K | 738,149 | — | ↗ |
| 2023-04-26 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 5,500 | 0.40 | 2.2K | 726,649 | — | ↗ |
| 2023-04-25 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,500 | 0.38 | 1.3K | 721,149 | — | ↗ |
| 2023-04-05 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 2,500 | 0.33 | 825.00 | 716,649 | — | ↗ |
| 2023-04-04 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 3,200 | 0.35 | 1.1K | 714,149 | — | ↗ |
| 2023-04-03 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 0.36 | 360.00 | 710,949 | — | ↗ |
| 2023-02-27 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 0.19 | 190.00 | 709,949 | — | ↗ |
| 2023-02-26 | Buttorff Leslie | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 1,000 | 0.19 | 190.00 | 706,949 | — | ↗ |
| 2022-12-31 | Buttorff Leslie | Officer | — | I | Common Stock | 0 | 0.00 | — | 4,047,054 | — | ↗ |
| 2022-08-26 | Buttorff Leslie | Officer | P-Purchase | A | Common Stock | 11,500 | 0.14 | 1.6K | 657,449 | — | ↗ |
| 2022-08-11 | Wert Lawrence | Director | P-Purchase | A | Common Stock | 5,000 | 0.13 | 640.00 | 1,317,868 | — | ↗ |
| 2022-08-03 | Buttorff Leslie | Officer | P-Purchase | A | Common Stock | 2,600 | 0.10 | 260.00 | 639,349 | — | ↗ |
| 2022-07-08 | Buttorff Leslie | Officer | P-Purchase | A | Common Stock | 2,100 | 0.40 | 835.59 | 627,149 | — | ↗ |
| 2022-04-04 | Buttorff Leslie | Officer | P-Purchase | A | Common Stock | 1,404 | 0.60 | 842.40 | 618,399 | — | ↗ |
| 2021-12-31 | Buttorff Leslie | Director / Officer / 10% Owner | — | I | Series C Preferred Stock | 0 | 0.00 | — | 1,000,000 | — | ↗ |
| 2021-10-17 | Nerger Janice | Director | — | D | Common Stock | 0 | 0.00 | — | 1,987,828 | — | ↗ |
| 2021-06-30 | Wert Lawrence | Director | A-Award | A | Stock Options (Right to Buy) | 28,000,000 | 0.10 | 2.80M | 28,000,000 | — | ↗ |
| 2021-06-30 | Buttorff Leslie | Director / Officer / 10% Owner | A-Award | A | Series D Preferred Stock | 10,000 | 0.00 | — | 10,000 | — | ↗ |
| 2021-06-30 | Berman Nathan Joel | Officer | A-Award | A | Common Stock | 496,957 | 0.00 | — | 496,957 | — | ↗ |
| 2021-06-30 | 22nd Century Group, Inc. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 91,016,026 | — | ↗ |
| 2021-05-04 | Kesner Harvey J | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 117,059 | — | ↗ |
| 2021-03-01 | Wert Lawrence | Director | A-Award | A | Common Stock | 3,500,000 | 0.00 | — | 8,620,297 | — | ↗ |
| 2021-01-22 | Alberttis Alvaro Daniel | Director / Officer | A-Award | A | Options to purchase common stock | 2,500,000 | 0.03 | 62.5K | 2,500,000 | — | ↗ |
| 2020-02-18 | Du Chesne Derek | Officer | — | D | Options to purchase common stock | 1,000,000 | 0.50 | 500.0K | 0 | — | ↗ |
| 2020-02-01 | Puzder Ken | Director / Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 500,000 | — | ↗ |
| 2020-02-01 | Johnson Andrew L. | Officer | A-Award | A | Common Stock | 250,000 | 0.00 | — | 1,106,250 | — | ↗ |
| 2020-01-16 | Alberttis Alvaro Daniel | Director | — | D | Common stock | 0 | 0.00 | — | 238,096 | — | ↗ |
| 2019-12-11 | Ceed2Med LLC | Director / 10% Owner | J-Other | D | Common Stock, Par Value $0.0001 per Share | 1,200,000 | 0.00 | — | 6,435,691 | — | ↗ |
| 2019-11-20 | Thompson Jeffrey M | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2019-11-20 | Price John C | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2019-11-20 | ESVAL KEVIN JAMES | Director | A-Award | A | Common Stock | 100,000 | 0.00 | — | 100,250 | — | ↗ |
| 2019-09-13 | Yampolsky Vladislav | Director / 10% Owner | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2019-09-13 | Aloi Emiliano Angel | Officer | A-Award | A | Common Stock | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2019-06-24 | Yampolsky Vladislav | Director / 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 7,635,690 | — | ↗ |
| 2019-06-24 | Schwartz Steven A | Director | — | D | Common Stock | 0 | 0.00 | — | 125,000 | — | ↗ |
| 2019-06-06 | Ceed2Med LLC | 10% Owner | D-Return | D | Common Stock | 750,000 | 0.30 | 225.0K | 7,635,690 | — | ↗ |
| 2019-03-12 | Johnson Andrew L. | Officer | — | D | Options to purchase common stock | 750,000 | 0.32 | 240.0K | 0 | — | ↗ |
| 2019-02-11 | Price John C | Director | — | D | Options to purchase common stock | 250,000 | 0.20 | 50.0K | 0 | — | ↗ |
| 2019-02-11 | GILBERT JONATHAN | Director / Officer | — | D | Options to purchase common stock | 1,000,000 | 0.01 | 10.0K | 0 | — | ↗ |
| 2019-01-15 | Johnson Andrew L. | Officer | — | D | Options to purchase common stock | 31,250 | 0.96 | 30.0K | 0 | — | ↗ |
| 2019-01-11 | Thompson Jeffrey M | Director | — | D | Options to purchase common stock | 2,000,000 | 0.03 | 50.0K | 0 | — | ↗ |
| 2019-01-11 | Puzder Ken | Director | — | D | Options to purchase common stock | 2,000,000 | 0.03 | 50.0K | 0 | — | ↗ |
| 2019-01-11 | ESVAL KEVIN JAMES | Director | — | I | Series B-2 Preferred Stock | 168,000 | 0.00 | — | 0 | — | ↗ |
| 2019-01-09 | Yampolsky Vladislav | Director / 10% Owner | — | D | Option (Right to Purchase) | 250,000 | 0.32 | 80.0K | 0 | — | ↗ |
| 2019-01-09 | Aloi Emiliano Angel | Officer | — | D | Options to purchase common stock | 250,000 | 0.32 | 80.0K | 0 | — | ↗ |
| 2019-01-08 | Ceed2Med LLC | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-09-12 | Ryan Timothy John | Director / Officer / 10% Owner | D-Return | D | Series D Preferred Stock (the | 16 | 0.00 | — | 16 | — | ↗ |
| 2018-09-04 | Young Philip J | Director / Officer | A-Award | A | Stock Options (Right to Buy) | 225,000 | 0.09 | 20.0K | 225,000 | — | ↗ |
| 2018-09-04 | Wendt Kelley A | Officer | A-Award | A | Stock Options (Right to Buy) | 225,000 | 0.09 | 20.0K | 225,000 | — | ↗ |
| 2018-09-04 | Ryan Timothy John | Director / Officer / 10% Owner | A-Award | A | Stock Options (Right to Buy) | 225,000 | 0.09 | 20.0K | 225,000 | — | ↗ |
| 2018-09-04 | Erickson James R. | Officer | A-Award | A | Stock Options (Right to Buy) | 1,000,000 | 0.09 | 89.0K | 1,000,000 | — | ↗ |
| 2018-07-05 | Ryan Timothy John | Director / Officer | A-Award | A | Series D Preferred Stock (the "Series D") | 16 | 0.00 | — | 27 | — | ↗ |
| 2018-03-28 | Young Philip J | Officer | A-Award | A | Series D Preferred Stock (the "Series D") | 11 | 0.00 | — | 11 | — | ↗ |
| 2018-03-28 | Wendt Kelley A | Officer | A-Award | A | Series D Preferred Stock (the "Series D") | 12 | 0.00 | — | 12 | — | ↗ |
| 2018-03-28 | Ryan Timothy John | Director / Officer | A-Award | A | Series D Preferred Stock (the "Series D") | 11 | 0.00 | — | 11 | — | ↗ |
| 2018-03-28 | Erickson James R. | Officer | A-Award | A | Series D Preferred Stock (the "Series D") | 6 | 0.00 | — | 6 | — | ↗ |
| 2017-08-18 | Young Philip J | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 8,520,000 | — | ↗ |
| 2017-08-18 | Wendt Kelley A | Officer | — | D | Series B-1 Preferred Stock | 600,000 | 0.00 | — | 0 | — | ↗ |
| 2017-08-18 | Ryan Timothy John | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 300,000 | — | ↗ |
| 2017-08-18 | Erickson James R. | Officer | — | D | Common Stock | 0 | 0.00 | — | 1,600,000 | — | ↗ |
| 2017-08-18 | Dimitrov Krassen | Director | — | I | Common Stock | 0 | 0.00 | — | 3,600,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-43.8K
Shares Outstanding
21.22M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Leslie A. Buttorff | Chairman, Chief Executive Officer & Chief Financial Officer | — | female |
| Nathan Joel Berman | Secretary & Principal Accounting Officer | — | male |
ESG Rating
ESG Score History DRUG MANUFACTURERS - SPECIALTY & GENERIC
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PLSH
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
